Label: ERGOLOID MESYLATES- dihydroergocornine mesylate, dihydroergocristine mesylate, dihydro-.alpha.-ergocryptine mesylate, and dihydro-.beta.-ergocryptine mesylate tablet

  • NDC Code(s): 53489-281-01, 53489-281-02, 53489-281-03, 53489-281-05, view more
  • Packager: Sun Pharmaceutical Industries, Inc.
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated November 22, 2017

If you are a consumer or patient please visit this version.


    Rx only


    Each tablet for oral use contains ergoloid mesylates USP; a mixture of the methanesulfonate salt of the following hydrogenated alkaloids:

    Chemical Structure










    C31H41N5O5 • CH4O3S (dihydroergocornine mesylate)

    C35H41N5O5 • CH4O3S (dihydroergocristine mesylate)

    C32H43N5O5 • CH4O3S (dihydro-α-ergocryptine mesylate)

    C32H43N5O5 • CH4O3S (dihydro-β-ergocryptine mesylate)

    exists as a mixture of alpha and beta isomers in a ratio of 2:1

    1 mg

    Dihydroergocristine mesylate

    0.333 mg

    Dihydroergocornine mesylate

    0.333 mg

    Dihydroergocryptine mesylate*

    0.333 mg

    Inactive ingredients for oral tablets are: butylated hydroxyanisol, corn starch, hydrogenated vegetable oil, lactose, mannitol, polyvinyl pyrrolidone, stearic acid and talc.


    There is no specific evidence which clearly establishes the mechanism by which ergoloid mesylates preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency.

    Pharmacokinetic Properties

    Pharmacokinetic studies have been performed in normal volunteers with the help of radiolabelled drug as well as employing a specific radioimmunoassay technique. From the urinary excretion quotient of orally and intravenously administered tritium-labelled ergoloid mesylates the absorption of ergoloid was calculated to be 25%. Following oral administration, peak levels of 0.5 ngEq/mL/mg were achieved within 1.5–3 hr. Bioavailability studies with the specific radioimmunoassay confirm that ergoloid is rapidly absorbed from the gastrointestinal tract, with mean peak levels of 0.05–0.13 ng/mL/mg (with extremes of 0.03 and 0.18 ng/mL/mg) achieved within 0.6–1.3 hr (with extremes of 0.4 and 2.8 hr). The finding of lower peak levels of ergoloid compared to the total drug-metabolite composite is consistent with a considerable first pass liver metabolism, with less than 50% of the therapeutic moiety reaching the systemic circulation. The elimination of radioactivity, representing ergoloid plus metabolites bearing the radiolabel, was biphasic with half-lives of 4 and 13 hr. The mean half-life of unchanged ergoloid in plasma is about 2.6–5.1 hr; after 3 half-lives ergoloid plasma levels are less than 10% of radioactivity levels, and by 24 hr no ergoloid is detectable.

    Bioequivalence studies were performed comparing ergoloid mesylates oral tablets (administered orally) with ergoloid mesylates sublingual tablets (administered sublingually). The oral tablet and sublingual tablet were shown to be bioequivalent.


    A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia).

    Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS).

    The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time.

    The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status.


    Ergoloid mesylates preparations are contraindicated in individuals who have previously shown hypersensitivity to the drug. Ergoloid mesylates preparations are also contraindicated in patients who have psychosis, acute or chronic, regardless of etiology.


    Practitioners are advised that because the target symptoms are of unknown etiology, careful diagnosis should be attempted before prescribing ergoloid mesylates preparations.


    Ergoloid mesylates preparations have not been found to produce serious side effects. Transient nausea and gastric disturbances have been reported. Ergoloid mesylates preparations do not possess the vasoconstrictor properties of the natural ergot alkaloids.


    1 mg three times a day.

    Alleviation of symptoms is usually gradual and results may not be observed for 3–4 weeks.


    Ergoloid mesylates tablets, USP (oral) 1 mg are white, round, unscored, debossed MP 20

    Bottles of 50                                                   NDC 53489-281-02
    Bottles of 100                                                 NDC 53489-281-01
    Bottles of 250                                                 NDC 53489-281-03
    Bottles of 500                                                 NDC 53489-281-05
    Bottles of 1000                                               NDC 53489-281-10

    Store at 20° to 25°C (68° to 77°F).
    [See USP Controlled Room Temperature]



    Distributed by: Sun Pharmaceutical Industries, Inc.
    Cranbury, NJ 08512

    Rev 02, August 2014

  • PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label

    Principal Display Panel - 100 Tablet Bottle Label
    dihydroergocornine mesylate, dihydroergocristine mesylate, dihydro-.alpha.-ergocryptine mesylate, and dihydro-.beta.-ergocryptine mesylate tablet
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:53489-281
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Dihydroergocornine Mesylate (UNII: 42RX8KPW29) (Dihydroergocornine - UNII:IK4C1OC8NE) Dihydroergocornine Mesylate0.333 mg
    Dihydroergocristine Mesylate (UNII: DS7CL18UAM) (Dihydroergocristine - UNII:05D48LUM4Z) Dihydroergocristine Mesylate0.333 mg
    Dihydro-.alpha.-ergocryptine mesylate (UNII: Z4I7BU58DN) (Dihydro-.alpha.-ergocryptine - UNII:202229IR8Y) Dihydro-.alpha.-ergocryptine mesylate0.222 mg
    Dihydro-.beta.-ergocryptine mesylate (UNII: 79Y4U49I29) (Epicriptine - UNII:5M64643B5U) Dihydro-.beta.-ergocryptine mesylate0.111 mg
    Inactive Ingredients
    Ingredient NameStrength
    butylated hydroxyanisole (UNII: REK4960K2U)  
    starch, corn (UNII: O8232NY3SJ)  
    hydrogenated cottonseed oil (UNII: Z82Y2C65EA)  
    mannitol (UNII: 3OWL53L36A)  
    povidone k90 (UNII: RDH86HJV5Z)  
    stearic acid (UNII: 4ELV7Z65AP)  
    talc (UNII: 7SEV7J4R1U)  
    Product Characteristics
    ColorWHITEScoreno score
    FlavorImprint Code MP;20
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:53489-281-0250 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product10/31/1991
    2NDC:53489-281-01100 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product10/31/1991
    3NDC:53489-281-03250 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product10/31/1991
    4NDC:53489-281-05500 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product10/31/1991
    5NDC:53489-281-101000 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product10/31/1991
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    Labeler - Sun Pharmaceutical Industries, Inc. (146974886)
    NameAddressID/FEIBusiness Operations
    Frontida BioPharm, Inc.080243260ANALYSIS(53489-281) , MANUFACTURE(53489-281) , PACK(53489-281)